Development of a novel, urine-based molecular assay for prediction of progression, recurrence, and need for definitive therapy on active surveillance for prostate cancer
- Abbreviated Name
- PASS_MPS
- Lead Investigator
- Chinnaiyan, Arul M. — University of Michigan
- Coordinating Investigator
- No coordinating investigator
- Involved Investigators
Abstact
n/a
Aims
Primary Aim: Evaluation of an existing, urine-based molecular assay to predict progression, need for definitive therapy, or recurrence for men on active surveillance for PCa. By identifying molecular metabolites in post-DRE urine of men on active surveillance in Canary PASS that are specific for aggressive disease, we will 1) evaluate the discriminative ability of our existing MPS assay for prediction of progression (GG≥3 on re-biopsy or pathology) 2) need for definitive treatment 3) or recurrence after treatment. Exploratory Aim: Development of a novel, urine-based molecular assay to predict progression, need for definitive therapy, or recurrence for men on active surveillance for PCa. By identifying molecular metabolites in post-DRE urine of men on active surveillance in Canary PASS, we will 1) assess for opportunities for improving the existing assay and/or 2) perform de novo creation of a novel biomarker to predict progression or recurrence.
Analytic Method
No analytic method available.
Publications
- No publications available at this time for this protocol.
Biomarkers
- No biomarkers available at this time for this protocol.
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- Feb 1 2023
- Estimated Finish Date
- Feb 1 2025
- Protocol ID
- 512
- Protocol Type
- Collaboration
- Field of Research
- UNKNOWN
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of prostate